E-mail

E-mail a Wiley Online Library Link

Matthew G. Fury, Nancy Y. Lee, Eric Sherman, Donna Lisa, Katherine Kelly, Brynna Lipson, Diane Carlson, Hilda Stambuk, Sofia Haque, Ronglai Shen, Dennis Kraus, Jatin Shah and David G. Pfister A phase 2 study of bevacizumab with cisplatin plus intensity-modulated radiation therapy for stage III/IVB head and neck squamous cell cancer Cancer 118

Version of Record online: 13 MAR 2012 | DOI: 10.1002/cncr.27498

For patients with stage III/IVB head and neck squamous cell cancer (HNSCC), the addition of bevacizumab to high-dose cisplatin plus intensity-modulated radiation therapy does not increase toxicity to unacceptable levels. Efficacy results are encouraging and further study of bevacizumab in HNSCC is warranted.

Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf

Required = Required Field

SEARCH